Abstract
Results An analysis of a series of haploid laboratory yeast strains revealed significant intra-strain variability and unstable plasmid segregation. By combining classic chemical mutagenesis and selection a family of highly efficient Saccharomyces cerevisiae strains has been developed for the commercial production of biopharmaceutical products. When combined with a stable [1], high copy number [2], episomal expression vector system and a strong constitutive promoter, secreted recombinant protein expression titres in excess of 4 g/L were achieved (see Figure 1). Specific genetic modifications to the host were also introduced to increase product yield and control posttranslational modifications, such as proteolysis and glycosylation.
Highlights
Enhanced protein expression through strain selection, gene disruption, improved vector design and co-expression of endogenous chaperones
The 4th Recombinant Protein Production Meeting: a comparative view on host physiology The organisers would like to thank Novozymes Delta Ltd who generously supported the meeting. Meeting abstracts – A single PDF containing all abstracts in this supplement is available here http://www.biomedcentral.com/content/pdf/1475-2859-5-S1-info.pdf
The use of Saccharomyces cerevisiae as a host system has been limited by the perception of limited secretion capacity, unstable episomal vectors and aberrant glycosylation
Summary
Enhanced protein expression through strain selection, gene disruption, improved vector design and co-expression of endogenous chaperones. Address: Novozymes Delta Ltd, Castle Court, 59 Castle Boulevard, Nottingham, UK * Corresponding author from The 4th Recombinant Protein Production Meeting: a comparative view on host physiology Barcelona, Spain. The 4th Recombinant Protein Production Meeting: a comparative view on host physiology The organisers would like to thank Novozymes Delta Ltd who generously supported the meeting. Meeting abstracts – A single PDF containing all abstracts in this supplement is available here http://www.biomedcentral.com/content/pdf/1475-2859-5-S1-info.pdf . The use of Saccharomyces cerevisiae as a host system has been limited by the perception of limited secretion capacity, unstable episomal vectors and aberrant glycosylation. Solutions to all of these limitations are available
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
